The Diabetes Control and Complication Trial (DCCT) highlighted the critical role of intensive insulin therapy (IIT) in reducing both microvascular and macrovascular complications among people with type 1 diabetes mellitus (T1DM) [5]. This evidence concerns the gene INS and type 1 diabetes mellitus.